Related Experiment Videos

[Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor]

Nicolas Mounier1, Stéphane Vignot, Jean-Philippe Spano

  • 1Service d'onco-hématologie, Hôpital de l'Archet 1, 151, route de Saint-Antoine-de-Ginestière, 06202 Nice.

Bulletin Du Cancer
|December 6, 2006
PubMed

Insights

Temsirolimus, an mTOR inhibitor, shows antiproliferative effects against cancers like breast, glioblastoma, and renal cell carcinoma. It is particularly effective in mantle-cell lymphoma, indicating its promise as a new cancer therapeutic.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Temsirolimus (CCI779) is an intravenous rapamycin analog.
  • It exhibits immunosuppressive and antiproliferative properties.
  • Its primary target is the mTOR serine/threonine kinase, crucial in carcinogenesis.

Purpose of the Study:

  • To evaluate the efficacy of temsirolimus in various cancers.
  • To identify specific cancer types with notable response rates.
  • To explore the potential of temsirolimus as a novel therapeutic agent.

Main Methods:

  • Clinical studies investigating temsirolimus in breast cancer, glioblastoma, and renal cell carcinoma.
  • Evaluation of response rates in these solid tumors.
  • Assessment of temsirolimus in hematological malignancies, specifically mantle-cell lymphoma.

Main Results:

  • Observed response rates of 10-20% in breast cancer, glioblastoma, and renal cell carcinoma.
  • Achieved a 40% response rate in mantle-cell lymphoma, linked to cyclin D1 activation.
  • These findings highlight temsirolimus's therapeutic potential.

Conclusions:

  • Temsirolimus demonstrates significant promise as a novel anti-cancer drug.
  • Its efficacy is particularly noted in mantle-cell lymphoma.
  • Future research will focus on combination therapies with chemotherapy.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...